Middle Meningeal Artery Embolization for Treating Subdural Hematoma in Canada A Study to Assess Safety and Effectiveness of EMMA Treatment

What this Trial Is About

Researchers are evaluating the safety and effectiveness of embolization of the middle meningeal artery EMMA to treat subdural hematoma CSDH. This prospective cohort study aims to see if EMMA reduces the recurrence of CSDH, either alone or alongside surgery. It focuses on patients presenting with CSDH diagnosed by CT scan, including those who may have recurrent hematomas or are on blood-thinning medications. All participants will receive embolization of the middle meningeal artery using embolic agents such as microparticles, liquid embolic agents, or coils. Patients needing urgent surgical evacuation will have surgery first, then may be considered for EMMA. EMMA may be used as primary treatment or combined with surgery, especially for those at higher risk of recurrence or who are not good candidates for surgery. Participants will be followed after hospital discharge at 1, 3, 6, and 12 months. A CT scan of the head will be performed at 3 months to assess hematoma recurrence and size. Clinical assessments will occur at 6 and 12 months. Researchers will track recurrence, symptoms, size changes, morbidity, mortality, and other health scores to evaluate outcomes and safety related to EMMA treatment.

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)